breastscape® v1.0
Olea MedicalProduct specifications |
Information source:
Vendor
Last updated: Feb. 7, 2022 |
General | |
---|---|
Product name | breastscape® v1.0 |
Company | Olea Medical |
Subspeciality | Breast |
Modality | MR |
Disease targeted | Breast cancer |
Key-features | Lesion segmentation and volumetry, DCE and ADC quantification, lesion follow-up, BI-RADS report, ACR classification, guidances for breast biopsy |
Suggested use | |
Data characteristics | |
Population | all patients for Breast MRI analysis |
Input | All series from MRI examination including morphologic and functionnal sequences (DCE, DWI). Mammography and US modalities can be loaded for examination comparison. |
Input format | DICOM |
Output | BI-RADS Report, DCE, DWI computation maps, lesion segmentation overlay |
Output format | DICOM-PDF or secondary capture (report), DICOM (imaging) |
Technology | |
Integration | Integration in standard reading environment (PACS), Stand-alone third party application |
Deployment | Locally on dedicated hardware, Locally virtualized (virtual machine, docker) |
Trigger for analysis | On demand, triggered by a user through e.g. a button click, image upload, etc. |
Processing time | BreastLoc: <3 sec, BreastApp: 1 - 10 minutes |
Certification | |
CE
|
Certified,
Class IIa
, MDD
|
FDA
|
510(k) cleared, Class II |
Market presence | |
On market since | 06-2018 |
Distribution channels | |
Countries present (clinical, non-research use) | |
Paying clinical customers (institutes) | |
Research/test users (institutes) | |
Pricing | |
Pricing model | Subscription |
Based on | Number of users |
Evidence | |
Peer reviewed papers on performance | |
Non-peer reviewed papers on performance | |
Other relevant papers |